Cyteir Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Cyteir Therapeutics's estimated annual revenue is currently $3.3M per year.
- Cyteir Therapeutics's estimated revenue per employee is $147,993
- Cyteir Therapeutics's total funding is $156.7M.
- Cyteir Therapeutics's current valuation is $216.5M. (January 2022)
Employee Data
- Cyteir Therapeutics has 22 Employees.
- Cyteir Therapeutics grew their employee count by -60% last year.
Cyteir Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | VP Clinical Operations | Reveal Email/Phone |
3 | VP, Clinical Operations | Reveal Email/Phone |
4 | Controller | Reveal Email/Phone |
5 | Associate Director | Reveal Email/Phone |
6 | Director, Process Chemistry | Reveal Email/Phone |
7 | Senior Director, Head Translational Research | Reveal Email/Phone |
8 | Chief Scientific Officer | Reveal Email/Phone |
9 | Senior Director, Head Analytical Chemistry | Reveal Email/Phone |
10 | General Counsel | Reveal Email/Phone |
Cyteir Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1M | 17 | 6% | N/A | N/A |
#2 | $13.4M | 131 | 10% | N/A | N/A |
#3 | $42.8M | 336 | 0% | N/A | N/A |
#4 | $7.8M | 76 | 0% | N/A | N/A |
#5 | $8.2M | 80 | 3% | N/A | N/A |
#6 | $0.1M | 6 | -25% | $1.9M | N/A |
#7 | $5.7M | 62 | 11% | N/A | N/A |
#8 | $0.9M | 14 | 0% | N/A | N/A |
#9 | $25.2M | 225 | 7% | N/A | N/A |
#10 | $6.3M | 71 | 13% | $1.7M | N/A |
What Is Cyteir Therapeutics?
Through a unique cancer treatment approach, Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.
keywords:N/A
$156.7M
Total Funding
22
Number of Employees
$3.3M
Revenue (est)
-60%
Employee Growth %
$216.5M
Valuation
N/A
Accelerator
Cyteir Therapeutics News
(Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will...
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies...
LEXINGTON, Mass., June 4, 2021 /PRNewswire/ -- Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the presentation of an interim analysis of the Phase 1 portion of a first-in-human Phase 1/2 study of CYT- ...
LEXINGTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an oversubscribed $80 million Series C financing. The company will use the new funds to advance ...
Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an oversubscribed $80 million Series C financing. The company will use the new funds to advance its lead compound, the first-in-class inhibitor of ...
Other Companies in Lexington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 22 | -12% | N/A |
#2 | $3.4M | 22 | -59% | N/A |
#3 | $3.8M | 22 | -12% | N/A |
#4 | $3.4M | 22 | 5% | N/A |
#5 | $3.2M | 22 | -8% | N/A |